| Title: | Predictors of Cardiovascular Disease in Individuals With Dysbetalipoproteinemia: A Prospective Study in the UK Biobank |
| Journal: | The Journal of Clinical Endocrinology & Metabolism |
| Published: | 7 Sep 2024 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/39243385/ |
| DOI: | https://doi.org/10.1210/clinem/dgae618 |
Publication 13545
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
BACKGROUND: Dysbetalipoproteinemia (DBL) is a disorder of remnant cholesterol metabolism associated with a severe risk of atherosclerotic cardiovascular disease (ASCVD).</p>
OBJECTIVE: The objective of this study was to investigate the univariate and multivariate predictors of ASCVD in individuals with DBL.</p>
METHODS: Data from 2,699 individuals with ε2/ε2 genotypes from the UK Biobank were included in this study. DBL was defined as having an ε2ε2 genotype with evidence of dyslipidemia, defined as total cholesterol ≥ 200 mg/dL [5.2 mmol/L] and TG ≥ 175 mg/dL [2.0 mmol/L]) or lipid-lowering therapy use (n=964).</p>
RESULTS: Age, hypertension, waist circumference and a polygenic risk score for coronary artery disease (PRSCAD) were independent predictors of ASCVD among individuals with DBL. Cumulative ASCVD-free survival was lower in the ε2/ε2 DBL group (84%) compared to the ε2/ε2 non-DBL group (94%) (p<0.0001), and for DBL individuals with a PRSCAD ≥ median (79%) compared to those with a PRSCAD < median (89%) (p=0.001).</p>
CONCLUSION: We show in a large prospective cohort that a PRSCAD predicts the ASCVD risk among individuals with DBL. The findings of the present study highlight the need for better risk stratification in ε2/ε2 carriers to identify high risk individuals that would need aggressive cardiovascular management despite their low apolipoprotein B value.</p>
5 Authors
- Martine Paquette
- Mark Trinder
- Simon-Pierre Guay
- Liam R Brunham
- Alexis Baass
1 Application
| Application ID | Title |
|---|---|
| 42857 | Influence of plasma lipoprotein genetics on infectious disease outcomes |
Enabling scientific discoveries that improve human health